About Puma Biotechnology
Puma Biotechnology is a company based in Los Angeles (United States) founded in 2010. It operates as a HealthTech. Puma Biotechnology has raised $60 million across 4 funding rounds from investors including BB Biotech. The company has 172 employees as of December 31, 2024. Puma Biotechnology offers products and services including Alisertib (ALISCA™-Lung1), Alisertib (ALISCA™-Breast1), and FDA Approved Treatment. Puma Biotechnology operates in a competitive market with competitors including Daré Bioscience, Atossa Therapeutics, Olema Oncology, PIQUR and Minerva Biotechnologies, among others.
- Headquarter Los Angeles, United States
- Employees 172 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Puma Biotechnology Inc
-
Annual Revenue
$230.47 M-2.19as on Dec 31, 2024
-
Net Profit
$30.28 M40.23as on Dec 31, 2024
-
EBITDA
$42.49 M-5.12as on Dec 31, 2024
-
Total Equity Funding
$60 M (USD)
in 4 rounds
-
Latest Funding Round
- Investors
-
Employee Count
172
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Puma Biotechnology
Puma Biotechnology is a publicly listed company on the NASDAQ with ticker symbol PBYI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Puma Biotechnology
Puma Biotechnology offers a comprehensive portfolio of products and services, including Alisertib (ALISCA™-Lung1), Alisertib (ALISCA™-Breast1), and FDA Approved Treatment. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational drug developed for small lung cancer treatment.
Investigational drug developed for metastatic breast cancer treatment.
Approved therapeutic developed for cancer treatment by Puma.
Unlock access to complete
Funding Insights of Puma Biotechnology
Puma Biotechnology has successfully raised a total of $60M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(05 Oct 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Post-IPO - Puma Biotechnology | Valuation |
investors |
|
| May, 2017 | Amount | Post-IPO - Puma Biotechnology | Valuation |
investors |
|
| Dec, 2011 | Amount | Series C - Puma Biotechnology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Puma Biotechnology
Puma Biotechnology has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include BB Biotech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Puma Biotechnology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Puma Biotechnology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Puma Biotechnology Comparisons
Competitors of Puma Biotechnology
Puma Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Atossa Therapeutics, Olema Oncology, PIQUR and Minerva Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for breast cancer treatment and prevention are developed.
|
|
| domain | founded_year | HQ Location |
Drug therapeutics for breast cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Anti-cancer drugs are developed via PI3K and mTOR inhibition targeting.
|
|
| domain | founded_year | HQ Location |
Cell therapy and antibodies are developed to treat cancer.
|
|
| domain | founded_year | HQ Location |
Small-molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Puma Biotechnology
Frequently Asked Questions about Puma Biotechnology
When was Puma Biotechnology founded?
Puma Biotechnology was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Where is Puma Biotechnology located?
Puma Biotechnology is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Is Puma Biotechnology a funded company?
Puma Biotechnology is a funded company, having raised a total of $60M across 4 funding rounds to date. The company's 1st funding round was a Series C of $5M, raised on Oct 05, 2011.
How many employees does Puma Biotechnology have?
As of Dec 31, 2024, the latest employee count at Puma Biotechnology is 172.
What is the annual revenue of Puma Biotechnology?
Annual revenue of Puma Biotechnology is $230.47M as on Dec 31, 2024.
What does Puma Biotechnology do?
Puma Biotechnology, Inc. is engaged in the acquisition, development, and commercialization of novel therapeutics aimed at treating various forms of cancer. The company is involved in clinical trials for investigational drugs like alisertib, targeting small lung cancer and metastatic breast cancer through programs such as ALISCA-Lung1 and ALISCA-Breast1. Additionally, an FDA-approved treatment for cancer is offered. The focus remains on advancing solutions within the biotechnology sector, specifically for oncology applications.
Who are the top competitors of Puma Biotechnology?
Puma Biotechnology's top competitors include Atossa Therapeutics, Daré Bioscience and Minerva Biotechnologies.
What products or services does Puma Biotechnology offer?
Puma Biotechnology offers Alisertib (ALISCA™-Lung1), Alisertib (ALISCA™-Breast1), and FDA Approved Treatment.
Is Puma Biotechnology publicly traded?
Yes, Puma Biotechnology is publicly traded on NASDAQ under the ticker symbol PBYI.
Who are Puma Biotechnology's investors?
Puma Biotechnology has 1 investor. Key investors include BB Biotech.
What is Puma Biotechnology's ticker symbol?
The ticker symbol of Puma Biotechnology is PBYI on NASDAQ.